Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Med Dosim ; 46(1): 74-79, 2021.
Article in English | MEDLINE | ID: mdl-32958360

ABSTRACT

To simulate an early 20th century viral pneumonia radiotherapy treatment using modern fluoroscopy and evaluated it according to current dose guidelines. Monte Carlo was used to assess the dose distribution on an anthropomorphic phantom. Critical organs were: skin, breasts, esophagus, ribs, vertebrae, heart, thymus, and spinal cord. A 100 kVp beam with 3 mm Al HVL, 25 × 25 cm2 posterior-anterior (PA) field and 50 cm source-to-surface distance were simulated. Simulations had a resolution of 0.4 × 0.4 × 0.06 cm3 and a 6% uncertainty. Hundred percent dose was normalized to the skin surface and results were displayed in axial, coronal, and sagittal planes. Dose volume histograms were generated in MATLAB for further analysis. Prescription doses of 0.3, 0.5, and 1.0 Gy were applied to the 15% isodose for organ-dose comparison to current tolerances and potential risk of detriment. Ninety-five and ninety-seven percent of the right and left lung volumes, respectively, were well-covered by the 15% isodose line. For the 0.3, 0.5, and 1.0 Gy prescriptions, the maximum skin doses were 2.9, 4.8, and 9.6 Gy compared to a 2.0 Gy transient erythema dose threshold; left/right lung maximum doses were 1.44/1.46, 2.4/2.4, and 4.8/4.9 Gy compared to a 6.5 Gy pneumonitis and 30 Gy fibrosis thresholds; maximum heart doses were 0.5, 0.9, and 1.8 Gy compared to the 0.5 Gy ICRP-recommendation; maximum spinal cord doses were 1.4, 2.3, and 4.6 Gy compared to 7.0 Gy single fraction dose threshold. Maximum doses to other critical organs were below modern dose thresholds. A 100 kVp PA field could deliver a 0.3 Gy or 0.5 Gy dose without risk of complications. However, a 1.0 Gy dose treatment could be problematic. Critical organ doses could be further reduced if more than one treatment field is used.


Subject(s)
Pneumonia , Radiotherapy Planning, Computer-Assisted , Fluoroscopy , Humans , Monte Carlo Method , Radiotherapy Dosage
2.
FEMS Microbiol Lett ; 333(1): 20-7, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22568688

ABSTRACT

Drug efflux pumps such as MexAB-OprM from Pseudomonas aeruginosa confer resistance to a wide range of chemically different compounds. Within the tripartite assembly, the inner membrane protein MexB is mainly responsible for substrate recognition. Recently, considerable advances have been made in elucidating the drug efflux pathway through the large periplasmic domains of resistance-nodulation-division (RND) transporters. However, little is known about the role of amino acids in other parts of the protein. We have investigated the role of two conserved phenylalanine residues that are aligned around the cytoplasmic side of the central cavity of MexB. The two conserved phenylalanine residues have been mutated to alanine residues (FAFA MexB). The interaction of the wild-type and mutant proteins with a variety of drugs from different classes was investigated by assays of cytotoxicity and drug transport. The FAFA mutation affected the efflux of compounds that have targets inside the cell, but antibiotics that act on cell wall synthesis and membrane probes were unaffected. Combined, our results indicate the presence of a hitherto unidentified cytoplasmic-binding site in RND drug transporters and enhance our understanding of the molecular mechanisms that govern drug resistance in Gram-negative pathogens.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Bacterial Outer Membrane Proteins/genetics , Cytoplasm/drug effects , Membrane Transport Proteins/genetics , Mutation , Pseudomonas aeruginosa/genetics , Alanine/genetics , Alanine/metabolism , Amino Acid Sequence , Amino Acid Substitution , Bacterial Outer Membrane Proteins/metabolism , Binding Sites , Biological Transport , Cell Membrane/metabolism , Cell Wall/metabolism , Cytoplasm/metabolism , Drug Resistance, Multiple, Bacterial , Erythromycin/pharmacokinetics , Escherichia coli/genetics , Escherichia coli/metabolism , Genes, Bacterial , Membrane Transport Proteins/metabolism , Microbial Sensitivity Tests , Molecular Sequence Data , Phenylalanine/genetics , Phenylalanine/metabolism , Plasmids/genetics , Plasmids/metabolism , Protein Structure, Tertiary , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/metabolism , Sequence Alignment , Substrate Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...